With the developments in gene therapy in Bbs mouse-models: improving the electrophysiological responses in Bbs4-/- mice, and the recent success in rescuing function in the Bbs10 model by sustainable effect on the improvement of rod- and cone responses over 1 year,69–71 2002 (Drack AV, et al. IOVS 2021; 62: ARVO E-Abstract 1178) the recent identification of a naturally occurring non-human primate model of BBS (type 7)72 and the success of RPE65 gene replacement therapy,73 there is enthusiasm and hope to make BBS-related retinal degeneration a treatable condition. This evidence concerns the gene RPE65 and Bardet-Biedl syndrome.